Narcolepsy Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Takeda, Jazz Pharmaceuticals, Taisho Pharma, Suven Life Sciences, Alza Corporation, Cephalon, Axsome

The Narcolepsy Market Forecast-2032 report offers an in-depth understanding of the Narcolepsy, historical and forecasted epidemiology as well as the Narcolepsy market trends in the 7MM.

DelveInsight’s “Narcolepsy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Narcolepsy, historical and forecasted epidemiology as well as the Narcolepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Narcolepsy, offering comprehensive insights into the Narcolepsy revenue trends, prevalence, and treatment landscape. The report delves into key Narcolepsy statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Narcolepsy therapies. Additionally, we cover the landscape of Narcolepsy clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Narcolepsy treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Narcolepsy space.

 

To Know in detail about the Narcolepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Narcolepsy Market Forecast

 

Some of the key facts of the Narcolepsy Market Report: 

  • The Narcolepsy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • Key Narcolepsy Companies: Jazz Pharmaceuticals, Taisho Pharmaceutical, Suven Life Sciences, Alza Corporation, Cephalon, Axsome Therapeutics, Inc., Takeda, Alkermes, Inc., Pfizer, Avadel, and others.

  • Key Narcolepsy Therapies: JZP258, TS-091L, SUVN-G3031, JNJ-17216498, Modafinil, AXS-12 (Reboxetine), TAK-861, ALKS 2680, PF-03654746, FT218, and others

  • The Narcolepsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Narcolepsy pipeline products will significantly revolutionize the Narcolepsy market dynamics.

  • According to the Narcolepsy Network Organization, an estimated 1 in every 2,000 individuals in the United States is affected by narcolepsy. This sleep disorder is often underdiagnosed and is more prevalent among adults than in children.

  • According to Slowik et al. (2022), narcolepsy type 1 has a prevalence of 14 per 100,000 individuals, while narcolepsy type 2 has a prevalence of 65.4 per 100,000. The disorder is most commonly diagnosed in individuals in their late teens to early twenties, with a 50% higher prevalence in females in the US, based on data from 2008─2010.

  • The Narcolepsy epidemiology based on gender analysed that females are more affected with narcolepsy (type1) than males

  • There is a significant unmet need for treatment options for narcolepsy patients. The pipeline is active with several promising candidates, including LUMRYZ (FT-218) by Avadel, Samelisant (SUVNG3031) from Suven Life Sciences, and Quilience by NLS Pharmaceutics, among others. Some of these treatments are anticipated to be launched during the forecast period from 2023 to 2032.

 

Narcolepsy Overview

Narcolepsy is a chronic neurological disorder that affects the brain’s ability to regulate sleep-wake cycles. People with narcolepsy often experience excessive daytime sleepiness and sudden episodes of falling asleep during the day, regardless of how much sleep they get at night. Other symptoms may include cataplexy (sudden loss of muscle tone), sleep paralysis, and hallucinations. The exact cause of narcolepsy is not fully understood, but it is believed to involve the loss of hypocretin-producing neurons in the brain, which play a key role in regulating wakefulness and REM sleep. Narcolepsy can significantly impact daily life, but symptoms can be managed with medication and lifestyle changes. 

 

Get a Free sample for the Narcolepsy Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/narcolepsy-market

 

Narcolepsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Narcolepsy Epidemiology Segmentation:

The Narcolepsy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Diagnosed Prevalent Cases of Narcolepsy in the 7MM

  • Subtype-specific Diagnosed Prevalent Cases of Narcolepsy in the 7MM

  • Age-specific Diagnosed Prevalent Cases of Narcolepsy in the 7MM

  • Treated Cases of Narcolepsy in the 7MM

 

Download the report to understand which factors are driving Narcolepsy epidemiology trends @ Narcolepsy Epidemiology Forecast

 

Narcolepsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Narcolepsy market or expected to get launched during the study period. The analysis covers Narcolepsy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Narcolepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Narcolepsy Therapies and Key Companies

  • JZP258: Jazz Pharmaceuticals

  • TS-091L: Taisho Pharmaceutical

  • SUVN-G3031: Suven Life Sciences

  • JNJ-17216498: Alza Corporation

  • Modafinil: Cephalon

  • AXS-12 (Reboxetine): Axsome Therapeutics, Inc.

  • TAK-861: Takeda

  • ALKS 2680: Alkermes, Inc.

  • PF-03654746: Pfizer

  • FT218: Avadel

 

Discover more about therapies set to grab major Narcolepsy market share @ Narcolepsy Treatment Landscape

 

Narcolepsy Market Strengths

  • Many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in narcolepsy.

  • The increasing prevalence of narcolepsy, for instance, knee pain associated with osteoarthritis, is primarily contributed by the increase in the aging population that will likely impact the market in the near future

 

Narcolepsy Market Opportunities

  • Identify potential therapeutic targets and strategies for improving quality of life, and restore functional levels of those who suffer from Narcolepsy

  • To understand the transition from acute to narcolepsy, how peripheral and central sensitization is manifested, and how they can be assessed

 

Scope of the Narcolepsy Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Narcolepsy Companies: Jazz Pharmaceuticals, Taisho Pharmaceutical, Suven Life Sciences, Alza Corporation, Cephalon, Axsome Therapeutics, Inc., Takeda, Alkermes, Inc., Pfizer, Avadel, and others

  • Key Narcolepsy Therapies: JZP258, TS-091L, SUVN-G3031, JNJ-17216498, Modafinil, AXS-12 (Reboxetine), TAK-861, ALKS 2680, PF-03654746, FT218, and others

  • Narcolepsy Therapeutic Assessment: Narcolepsy current marketed and Narcolepsy emerging therapies

  • Narcolepsy Market Dynamics: Narcolepsy market drivers and Narcolepsy market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Narcolepsy Unmet Needs, KOL’s views, Analyst’s views, Narcolepsy Market Access and Reimbursement 

 

To know more about Narcolepsy companies working in the treatment market, visit @ Narcolepsy Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Narcolepsy Market Report Introduction

2. Executive Summary for Narcolepsy

3. SWOT analysis of Narcolepsy

4. Narcolepsy Patient Share (%) Overview at a Glance

5. Narcolepsy Market Overview at a Glance

6. Narcolepsy Disease Background and Overview

7. Narcolepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Narcolepsy 

9. Narcolepsy Current Treatment and Medical Practices

10. Narcolepsy Unmet Needs

11. Narcolepsy Emerging Therapies

12. Narcolepsy Market Outlook

13. Country-Wise Narcolepsy Market Analysis (2019–2032)

14. Narcolepsy Market Access and Reimbursement of Therapies

15. Narcolepsy Market Drivers

16. Narcolepsy Market Barriers

17.  Narcolepsy Appendix

18. Narcolepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Narcolepsy Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Takeda, Jazz Pharmaceuticals, Taisho Pharma, Suven Life Sciences, Alza Corporation, Cephalon, Axsome